Published in J Proteome Res on June 04, 2010
Ketogenic Diet Therapy for Autism Spectrum Disorder | NCT02477904
Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry (2011) 2.28
The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol (2011) 2.26
Metabolic phenotyping in clinical and surgical environments. Nature (2012) 2.09
In search of biomarkers for autism: scientific, social and ethical challenges. Nat Rev Neurosci (2011) 2.07
Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity. Nutr Metab (Lond) (2011) 1.58
Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders. Microb Ecol Health Dis (2012) 1.35
The role of microbiome in central nervous system disorders. Brain Behav Immun (2013) 1.34
Low relative abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium spp. in feces of children with autism. Appl Environ Microbiol (2011) 1.27
Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. Metabolomics (2014) 1.24
The mind-body-microbial continuum. Dialogues Clin Neurosci (2011) 1.20
Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: INTERMAP study. J Proteome Res (2010) 1.15
Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol Cell Proteomics (2012) 1.15
The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. Gut Microbes (2012) 1.12
Urinary N-methylnicotinamide and β-aminoisobutyric acid predict catch-up growth in undernourished Brazilian children. Sci Rep (2016) 1.10
The microbiota-gut-brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both? J Physiol (2014) 1.07
Nutritional lipidomics: molecular metabolism, analytics, and diagnostics. Mol Nutr Food Res (2013) 1.03
Alterations in the Vaginal Microbiome by Maternal Stress Are Associated With Metabolic Reprogramming of the Offspring Gut and Brain. Endocrinology (2015) 1.02
Biomarkers in autism spectrum disorder: the old and the new. Psychopharmacology (Berl) (2013) 1.01
Combined application of NMR- and GC-MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorder. Sci Rep (2014) 0.99
Decreased tryptophan metabolism in patients with autism spectrum disorders. Mol Autism (2013) 0.97
Modulatory Effects of Gut Microbiota on the Central Nervous System: How Gut Could Play a Role in Neuropsychiatric Health and Diseases. J Neurogastroenterol Motil (2016) 0.97
The potential role of probiotics in the management of childhood autism spectrum disorders. Gastroenterol Res Pract (2011) 0.96
Clinical metabolomics paves the way towards future healthcare strategies. Br J Clin Pharmacol (2013) 0.95
Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis. Arthritis Res Ther (2011) 0.93
Autism: metabolism, mitochondria, and the microbiome. Glob Adv Health Med (2013) 0.93
Development of an integrated metabolomic profiling approach for infectious diseases research. Analyst (2011) 0.92
Sex-specific urinary biomarkers for diagnosing bipolar disorder. PLoS One (2014) 0.91
Biochemical screening and PTEN mutation analysis in individuals with autism spectrum disorders and macrocephaly. Eur J Hum Genet (2013) 0.90
Altered metabolites in the plasma of autism spectrum disorder: a capillary electrophoresis time-of-flight mass spectroscopy study. PLoS One (2013) 0.86
Current progress and challenges in the search for autism biomarkers. Dis Markers (2013) 0.85
The potential role of the antioxidant and detoxification properties of glutathione in autism spectrum disorders: a systematic review and meta-analysis. Nutr Metab (Lond) (2012) 0.85
Environment, dysbiosis, immunity and sex-specific susceptibility: a translational hypothesis for regressive autism pathogenesis. Nutr Neurosci (2014) 0.84
Genetic determinants of metabolism in health and disease: from biochemical genetics to genome-wide associations. Genome Med (2012) 0.83
Prenatal and perinatal analgesic exposure and autism: an ecological link. Environ Health (2013) 0.83
Integrative analysis of genetic data sets reveals a shared innate immune component in autism spectrum disorder and its co-morbidities. Genome Biol (2016) 0.82
Dog bites man or man bites dog? The enigma of the amino acid conjugations. Biochem Pharmacol (2011) 0.82
Metabolic phenotyping and systems biology approaches to understanding neurological disorders. F1000Prime Rep (2013) 0.82
Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children. PLoS One (2014) 0.81
Human Microbiome: When a Friend Becomes an Enemy. Arch Immunol Ther Exp (Warsz) (2015) 0.80
Immunostimulation in the era of the metagenome. Cell Mol Immunol (2011) 0.79
Nutrigenomics and personalized diets: What will they mean for food? Annu Rev Food Sci Technol (2011) 0.79
Urinary metabonomics for diagnosis of depression in hepatitis B virus-infected patients. Iran Red Crescent Med J (2015) 0.78
Nicotinamide, NAD(P)(H), and Methyl-Group Homeostasis Evolved and Became a Determinant of Ageing Diseases: Hypotheses and Lessons from Pellagra. Curr Gerontol Geriatr Res (2012) 0.78
Urinary Biomarkers of Brain Diseases. Genomics Proteomics Bioinformatics (2016) 0.77
Does our gut microbiome predict cardiovascular risk? A review of the evidence from metabolomics. Circ Cardiovasc Genet (2015) 0.77
MIRA: mutual information-based reporter algorithm for metabolic networks. Bioinformatics (2014) 0.77
In vitro fermentation of B-GOS: impact on faecal bacterial populations and metabolic activity in autistic and non-autistic children. FEMS Microbiol Ecol (2016) 0.76
The Implications of Metabotypes for Rationalizing Therapeutics in Infants and Children. Front Pediatr (2015) 0.76
The Brain-Gut-Microbiome Axis: What Role Does It Play in Autism Spectrum Disorder? Curr Dev Disord Rep (2016) 0.76
Early infant exposure to excess multivitamin: a risk factor for autism? Autism Res Treat (2013) 0.76
Novel systems modeling methodology in comparative microbial metabolomics: identifying key enzymes and metabolites implicated in autism spectrum disorders. Int J Mol Sci (2015) 0.76
Gut Microbiota and Autism: Key Concepts and Findings. J Autism Dev Disord (2016) 0.76
Potential serum biomarkers from a metabolomics study of autism. J Psychiatry Neurosci (2016) 0.75
Body fluid levels of neuroactive amino acids in autism spectrum disorders: a review of the literature. Amino Acids (2016) 0.75
Unravelling the metabolic impact of SBS-associated microbial dysbiosis: Insights from the piglet short bowel syndrome model. Sci Rep (2017) 0.75
Urinary amino acid alterations in 3-year-old children with neurodevelopmental effects due to perinatal dioxin exposure in Vietnam: a nested case-control study for neurobiomarker discovery. PLoS One (2015) 0.75
Urinary metabolomics of young Italian autistic children supports abnormal tryptophan and purine metabolism. Mol Autism (2016) 0.75
Host-gut microbiota metabolic interactions. Science (2012) 7.73
Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science (2013) 6.98
Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics (2007) 6.93
Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A (2008) 6.42
Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov (2002) 5.96
Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc (2007) 5.92
Human metabolic phenotype diversity and its association with diet and blood pressure. Nature (2008) 5.41
Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol (2005) 5.35
Systems biology: Metabonomics. Nature (2008) 5.32
Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A (2006) 5.19
Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem (2005) 4.14
Chemometrics in metabonomics. J Proteome Res (2007) 4.02
Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med (2002) 3.91
A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol Syst Biol (2007) 3.68
Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature (2006) 3.45
Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut (2011) 3.42
Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Sci Transl Med (2013) 3.26
Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A (2009) 3.01
Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med (2006) 2.95
Summary recommendations for standardization and reporting of metabolic analyses. Nat Biotechnol (2005) 2.90
Multiple parasite infections and their relationship to self-reported morbidity in a community of rural Côte d'Ivoire. Int J Epidemiol (2004) 2.84
Metabolic phenotyping in health and disease. Cell (2008) 2.80
Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov (2008) 2.59
Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci U S A (2010) 2.52
Gut microbiome-host interactions in health and disease. Genome Med (2011) 2.48
Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol (2008) 2.43
Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc (2010) 2.18
Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol (2008) 2.17
UPLC/MS(E); a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Commun Mass Spectrom (2006) 2.17
NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed (2005) 2.15
Metabonomic investigations in mice infected with Schistosoma mansoni: an approach for biomarker identification. Proc Natl Acad Sci U S A (2004) 2.11
Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res (2009) 2.10
Metabolic phenotyping in clinical and surgical environments. Nature (2012) 2.09
Colonization-induced host-gut microbial metabolic interaction. MBio (2011) 2.04
The challenges of modeling mammalian biocomplexity. Nat Biotechnol (2004) 2.03
Optimized preprocessing of ultra-performance liquid chromatography/mass spectrometry urinary metabolic profiles for improved information recovery. Anal Chem (2011) 2.02
Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol (2006) 1.99
Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res (2007) 1.99
How has healthcare research performance been assessed?: a systematic review. J R Soc Med (2011) 1.97
Susceptibility of human metabolic phenotypes to dietary modulation. J Proteome Res (2006) 1.96
High resolution "ultra performance" liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J Proteome Res (2005) 1.93
Metabonomics in pharmaceutical R&D. FEBS J (2007) 1.93
Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem (2004) 1.88
The human gut microbiome: implications for future health care. Curr Gastroenterol Rep (2008) 1.84
Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res (2010) 1.84
A genome-wide metabolic QTL analysis in Europeans implicates two loci shaped by recent positive selection. PLoS Genet (2011) 1.83
Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal Chem (2006) 1.81
Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers (2004) 1.79
Global metabolic responses of NMRI mice to an experimental Plasmodium berghei infection. J Proteome Res (2008) 1.78
NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol (2008) 1.77
Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal Chem (2006) 1.76
High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc (2010) 1.76